Biotech · Private company
ARMO BioSciences
Track this companyFree. Adds ARMO BioSciences to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials7
- Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerPHASE2 · TERMINATED · started Mar 22, 2018ClinicalTrials.gov NCT03382912 · fetched Nov 12, 2026
- Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerPHASE2 · TERMINATED · started Mar 19, 2018ClinicalTrials.gov NCT03382899 · fetched Nov 12, 2026
- A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy ParticipantsPHASE1 · COMPLETED · started Jan 19, 2018ClinicalTrials.gov NCT04194892 · fetched Nov 12, 2026
- A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)PHASE1 · COMPLETED · started Dec 18, 2017ClinicalTrials.gov NCT03381547 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)PHASE1 · COMPLETED · started Sep 5, 2017ClinicalTrials.gov NCT03267732 · fetched Nov 12, 2026
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic CancerPHASE3 · COMPLETED · started Mar 1, 2017ClinicalTrials.gov NCT02923921 · fetched Nov 12, 2026
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Nov 15, 2013ClinicalTrials.gov NCT02009449 · fetched Nov 12, 2026